PL4074377T3 - Sposoby optymalizacji leczenia zaburzeń psychicznych za pomocą kannabidiolu i kompozycje farmaceutyczne zawierające kannabidiol - Google Patents

Sposoby optymalizacji leczenia zaburzeń psychicznych za pomocą kannabidiolu i kompozycje farmaceutyczne zawierające kannabidiol

Info

Publication number
PL4074377T3
PL4074377T3 PL21167887.5T PL21167887T PL4074377T3 PL 4074377 T3 PL4074377 T3 PL 4074377T3 PL 21167887 T PL21167887 T PL 21167887T PL 4074377 T3 PL4074377 T3 PL 4074377T3
Authority
PL
Poland
Prior art keywords
cannabidiol
optimizing
treatment
methods
pharmaceutical compositions
Prior art date
Application number
PL21167887.5T
Other languages
English (en)
Inventor
Franz-Markus Leweke
Original Assignee
Curantis Ug
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curantis Ug filed Critical Curantis Ug
Publication of PL4074377T3 publication Critical patent/PL4074377T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL21167887.5T 2021-04-12 2021-04-12 Sposoby optymalizacji leczenia zaburzeń psychicznych za pomocą kannabidiolu i kompozycje farmaceutyczne zawierające kannabidiol PL4074377T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21167887.5A EP4074377B1 (en) 2021-04-12 2021-04-12 Methods for optimizing treatment of mental disorders with cannabidiol and pharmaceutical compositions comprising cannabidiol

Publications (1)

Publication Number Publication Date
PL4074377T3 true PL4074377T3 (pl) 2025-08-18

Family

ID=75477957

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21167887.5T PL4074377T3 (pl) 2021-04-12 2021-04-12 Sposoby optymalizacji leczenia zaburzeń psychicznych za pomocą kannabidiolu i kompozycje farmaceutyczne zawierające kannabidiol

Country Status (12)

Country Link
US (1) US20240192237A1 (pl)
EP (2) EP4541350A3 (pl)
JP (1) JP7634777B2 (pl)
CN (1) CN117320702A (pl)
BR (1) BR112023020839A2 (pl)
CA (1) CA3214976A1 (pl)
ES (1) ES3032936T3 (pl)
HR (1) HRP20250698T1 (pl)
HU (1) HUE071635T2 (pl)
PL (1) PL4074377T3 (pl)
SM (1) SMT202500224T1 (pl)
WO (1) WO2022218930A2 (pl)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3302437T4 (da) 2015-05-28 2026-02-23 Fresh Cut Dev Llc Stabile cannabinoidformuleringer
CN106074464A (zh) * 2016-06-14 2016-11-09 云南瑞酚生物科技有限公司 大麻二酚在制备治疗痛风药物中的应用
EP3724657A4 (en) 2017-12-15 2021-12-29 Bomi, Llc Anti-cannabidiol antibody and uses thereof
US11179340B2 (en) * 2017-12-29 2021-11-23 TGC Network LLC Cannabidiol dosage form
US20200375911A1 (en) 2019-06-03 2020-12-03 Fresh Cut Development, Llc Cannabidiol nanocrystal compositions
CN111991355B (zh) * 2019-12-30 2023-06-23 云南汉盟制药有限公司 含纳米级大麻二酚的固体纳米粉组合物、制备方法及用途

Also Published As

Publication number Publication date
HUE071635T2 (hu) 2025-09-28
JP7634777B2 (ja) 2025-02-21
BR112023020839A2 (pt) 2023-12-12
EP4074377B1 (en) 2025-03-12
EP4541350A3 (en) 2025-10-15
ES3032936T3 (en) 2025-07-29
HRP20250698T1 (hr) 2025-09-12
EP4541350A2 (en) 2025-04-23
EP4074377C0 (en) 2025-03-12
WO2022218930A2 (en) 2022-10-20
JP2024514716A (ja) 2024-04-02
US20240192237A1 (en) 2024-06-13
CN117320702A (zh) 2023-12-29
EP4074377A1 (en) 2022-10-19
CA3214976A1 (en) 2022-10-20
WO2022218930A3 (en) 2023-01-05
SMT202500224T1 (it) 2025-07-22

Similar Documents

Publication Publication Date Title
IL289975A (en) Use of cannabidiol in the treatment of dravet syndrome
MX380767B (es) Métodos para reducir el riesgo cardiovascular.
MX376835B (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
SI3377637T1 (sl) Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože
CL2015003442A1 (es) Derivados heterociclicos
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
PH12016500862A1 (en) Autotaxin inhibitor compounds
BR112017027836A2 (pt) método para o tratamento de inflamação usando compostos naturais e/ou dieta
EP2849738A4 (en) HIGH-POWDER PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF LUNG DISEASES
EP3952840A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL BEHAVIOR COGNITIVE DISORDERS
EP3672587A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
PL3956310T3 (pl) <div>MODYFIKOWANE POCHODNE AMINOKWASÓW DO LECZENIA CHORÓB NEUROLOGICZNYCH I WYBRANYCH ZABURZEŃ PSYCHICZNYCH</div>
EP4426291A4 (en) Indolizine compounds for the treatment of mental disorders or for mental improvement
EP3581175A4 (en) PREPARATION FOR THE ADMINISTRATION OF A DRUG FOR THE TREATMENT OF MENTAL ILLNESSES OR CENTRAL NERVOUS SYSTEM DISORDERS
EP4008718C0 (en) HETEROARYLAMIDOPYRIDINOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING AUTOIMMUNE DISEASE
EP3566702A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ALLERGIC DISEASES SUCH AS ASTHMA OR ATOPIA, CONSISTING OF BAICALEIN AS THE ACTIVE SUBSTANCE
IL279745A (en) Methods for treating or preventing conformation diseases and methods for drug screening
EP4058017A4 (en) MEDICINAL FORMULATIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS
EP3570835A4 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF IMMUNINFLAMMABLE DERMAL DISEASES
BR112018071972A2 (pt) métodos para tratamento ou prevenção de uma doença ou distúrbio de fígado, para tratamento de câncer de fígado e para tratamento de inflamação no fígado, trato biliar ou pâncreas de um animal, alfa-defensina e/ou ss-defensina de mamífero e/ou uma catelicidina e/ou um análogo de glp-1, e, uso dos mesmos.
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
EP3518951A4 (en) COMPOSITIONS AND METHODS FOR TREATING ORTHOPEDIC COMPLAINTS
EP3552632A4 (en) MEDICINAL COMPOSITION FOR TREATING AND PREVENTING CHRONIC DISEASE
IL308083A (en) Methods and compositions for treatment of diabetic retinopathy and related conditions
CL2021000858A1 (es) Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento